Loading

Please wait...

Metoclopramide odt

Generic Name: metoclopramide (oral/injection) (MET oh KLOE pra mide)
Brand Names: Metozolv ODT, Reglan
Metoclopramide is used short-term to treat heartburn caused by gastroesophageal reflux. Learn about side effects, interactions and indications.
  • Prescription Settings
  • X

Prices and coupons of Metoclopramide odt

Set your location
for drug prices near you

Enter your zip code

Don’t see your pharmacy listed? Most pharmacies accept our discounts, so have your pharmacist enter this coupon to see if you will save money:

Drug Information:
Metoclopramide increases muscle contractions in the upper digestive tract. This speeds up the rate at which the stomach empties into the intestines. Metoclopramide oral (taken by mouth) is used for 4 to 12 weeks to treat heartburn caused by gastroesophageal reflux in people who have used other medications without relief. Metoclopramide oral is also used to treat gastroparesis (slow stomach emptying) in people with diabetes, which can cause heartburn and stomach discomfort after meals. Metoclopramide injection is used to treat severe diabetic gastroparesis. The injection is also used to prevent nausea and vomiting caused by chemoTherapy or surgery, or to aid in certain medical procedures involving the stomach or intestines. Learn more

Metoclopramide odt Side Effects

Metoclopramide Side Effects

For the Consumer

Applies to metoclopramide: oral solution, oral tablet, oral tablet disintegrating

Other dosage forms:

  • solution

Warning

Oral route (Tablet)

Metoclopramide can cause tardive dyskinesia, a serious movement disorder that is often irreversible. The risk of developing tardive dyskinesia increases with duration of treatment and total cumulative dose. Discontinue metoclopramide in patients who develop signs or symptoms of tardive dyskinesia. There is no known treatment for tardive dyskinesia. In some patients, symptoms may lessen or resolve after metoclopramide is stopped. Avoid treatment with Reglan for longer than 12 weeks because of the increased risk of developing TD with longer-term use.

Oral route (Tablet, Disintegrating; Solution)

Metoclopramide treatment can cause tardive dyskinesia, a serious movement disorder that is often irreversible. Risk is increased with duration of treatment and total cumulative dose. Discontinue metoclopramide therapy in patients who develop signs or symptoms of tardive dyskinesia. There is no known treatment for tardive dyskinesia, although symptoms may lessen or resolve after metoclopramide discontinuation. Prolonged treatment with metoclopramide (greater than 12 weeks) should be avoided in all but rare cases where therapeutic benefit outweighs the risks.

Along with its needed effects, metoclopramide may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking metoclopramide:

Incidence not known

  • Chills
  • clay colored stools
  • dark urine
  • difficulty with breathing
  • difficulty with speaking or swallowing
  • dizziness or fainting
  • fast or irregular heartbeat
  • fever
  • general feeling of tiredness or weakness
  • headache (severe or continuing)
  • inability to move the eyes
  • increase in blood pressure
  • increased sweating
  • itching, skin rash
  • lip smacking or puckering
  • loss of appetite
  • loss of balance control
  • loss of bladder control
  • mask-like face
  • muscle spasms of the face, neck, and back
  • nausea
  • puffing of the cheeks
  • rapid or worm-like movements of the tongue
  • seizures
  • shuffling walk
  • sore throat
  • stiffness of the arms or legs
  • stomach pain or tenderness
  • swelling of the feet or lower legs
  • tic-like or twitching movements
  • trembling and shaking of the hands and fingers
  • twisting movements of the body
  • uncontrolled chewing movements
  • uncontrolled movements of the arms and legs
  • unusually pale skin
  • vomiting
  • weakness of the arms and legs
  • yellow eyes or skin

Get emergency help immediately if any of the following symptoms of overdose occur while taking metoclopramide:

Symptoms of overdose

  • Confusion
  • drowsiness (severe)

Some side effects of metoclopramide may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

  • Diarrhea
  • drowsiness
  • loss of strength or energy
  • muscle pain or weakness
  • restlessness
  • unusual weak feeling

Incidence not known

  • Breast tenderness and swelling
  • changes in menstruation
  • constipation
  • decreased interest in sexual intercourse
  • inability to have or keep an erection
  • increased flow of breast milk
  • increased need to urinate
  • loss in sexual ability, desire, drive, or performance
  • mental depression
  • passing urine more often
  • skin rash
  • trouble sleeping
  • unusual dryness of the mouth
  • unusual irritability

For Healthcare Professionals

Applies to metoclopramide: compounding powder, injectable solution, oral concentrate, oral syrup, oral tablet, oral tablet disintegrating

General

The incidence of side effects correlates with dose and duration of metoclopramide therapy.

Nervous system

Drowsiness, decreased level of consciousness, confusion, and hallucinations have higher incidences with higher doses.

Convulsive seizures have been reported, especially in patients with epilepsy; however, there is no obvious association with use of this drug.

Dystonic reactions typically presented as upper airway obstruction with stridor and dyspnea.

Parkinsonian symptoms may be related to usual/excessive doses and/or decreased renal function and includes tremor, rigidity, bradykinesia, and akinesia.

Very common (10% or more): Drowsiness (up to 70%), acute dystonic reaction (up to 25%)

Common (1% to 10%): Akathisia, dizziness, extrapyramidal disorders, headache, parkinsonism, somnolence

Uncommon (0.1% to 1%): Depressed level of consciousness, dyskinesia, dystonia

Rare (0.01% to 0.1%): Bradykinesia, convulsion, dystonic reaction, tremor

Very rare (less than 0.01%): Neuroleptic malignant syndrome

Frequency not reported: Acute dyskinesia, acute dystonia/acute dystonic reaction, altered consciousness, autonomic instability, bulbar type of speech, choreoathetotic movements, cogwheel rigidity, convulsive seizures, extrapyramidal symptoms, facial grimacing, facial muscle spasm, fatal dystonic reaction, foot tapping, inability to sit still, involuntary movements of the extremities/face/jaw/mouth/tongue/trunk, mask-like facies, motor restlessness, opisthotonos, pacing, parkinsonian syndrome, rhythmic tongue protrusion, serotonin syndrome, syncope, tardive dyskinesia, tetanus-like reaction, unnatural position of head and shoulders

Gastrointestinal

Common (1% to 10%): Diarrhea, nausea, vomiting

Uncommon (0.1% to 1%): Bowel disturbances

Rare (0.01% to 0.1%): Supraglottic dystonia

Frequency not reported: Glossal edema

Other

Common (1% to 10%): Asthenia, fatigue, lassitude

Frequency not reported: Effects on the ability to drive/operate machinery, hyperpyrexia, hyperthemia, jitteriness

Psychiatric

Common (1% to 10%): Depression, restlessness

Uncommon (0.1% to 1%): Hallucination, insomnia

Rare (0.01% to 0.1%): Acute depression, confusional state

Frequency not reported: Agitation, anxiety, confusion, delirium, mania, mental depression with suicidal ideation, nervousness, obsessive rumination, severe dysphoria, suicidal ideation, suicide

Cardiovascular

Hypotension, bradycardia, shock, and other abnormalities or cardiac conduction occurred most frequently with IV formulations.

Cardiac arrest occurred shortly after IV administration, and may have been subsequent to bradycardia.

Sinus arrest and transient facial/upper body flushing occurred, particularly with IV administration. Flushing typically occurred without alterations in vital signs following high dose IVs.

Edema/fluid retention may be secondary to a transient increase in aldosterone levels.

Acute hypertension has occurred in patients with pheochromocytoma.

Hypertension has occurred in patients with/without pheochromocytoma.

Common (1% to 10%): Hypotension

Uncommon (0.1% to 1%): Bradycardia

Very rare (less than 0.01%): Cardiac conduction abnormalities, heart block

Frequency not reported: Acute congestive heart failure, acute hypertension, atrial fibrillation, atrioventricular (AV) block, cardiac arrest, edema, electrocardiogram QT prolonged, fatal cardiorespiratory arrest, hypertension, palpitation, possible AV block, shock, sinus arrest, supraventricular tachycardia, tachycardia, Torsade de Pointes, transient facial/upper body flushing, transient increase in blood pressure, ventricular fibrillation, ventricular tachycardia

Genitourinary

Impotence may be secondary to hyperprolactinemia.

Uncommon (0.1% to 1%): Amenorrhea

Rare (0.01% to 0.1%): Galactorrhea

Frequency not reported: Breast enlargement, impotence, priapism, sexual dysfunction, urinary frequency, urinary incontinence

Endocrine

Uncommon (0.1% to 1%): Hyperprolactinemia

Frequency not reported: Endocrine disorders, gynecomastia, transient aldosterone elevation

Amenorrhea, galactorrhea, and gynecomastia occurred secondary to hyperprolactinemia during prolonged treatment.

Hypersensitivity

Anaphylactic reaction/shock typically occurred with the IV formulation.

Uncommon (0.1% to 1%): Hypersensitivity

Frequency not reported: Anaphylactic reaction, anaphylactic shock, angioedema

Respiratory

Rare (0.01% to 0.1%): Dyspnea, laryngospasm, stridor, upper airway obstruction

Frequency not reported: Acute asthmatic symptoms, bronchospasm, laryngeal edema, respiratory failure, wheezing

Bronchospasm, wheezing, and dyspnea typically occurred in patients with a history of asthma.

Respiratory failure occurred secondary to dystonic reactions.

Hepatic

Hepatotoxicity occurred with concurrent use of other potentially hepatotoxic drugs and was characterized by findings such as jaundice and altered liver function tests.

Rare (0.01% to 0.1%): Altered liver function tests, hepatotoxicity, jaundice

Musculoskeletal

Rare (0.01% to 0.1%): Rigidity

Frequency not reported: Fluid retention, generalized muscle tone increase, increased creatinine phosphokinase (CPK), muscle rigidity, muscle spasms, torticollis, trismus

Hematologic

Leukopenia, neutropenia, and agranulocytosis typically did not have a clear-cut relationship with this drug.

Methemoglobinemia and sulfhemoglobinemia occurred with high doses of this drug. Methemoglobinemia may be related to NADH cytochrome b5 reductase deficiency or overdose, particularly in neonates. Sulfhemoglobinemia usually occurred in adults with concomitant use of high doses of sulfur-releasing products.

Frequency not reported: Agranulocytosis, blood disorders, leukopenia, methemoglobinemia, neutropenia, sulfhemoglobinemia

Dermatologic

Frequency not reported: Angioneurotic edema, maculopapular rash, rash, urticaria

Rash and urticaria typically occurred in patients with a history of asthma.

Ocular

Frequency not reported: Extraocular muscle spasm, oculogyric crisis, visual disturbances

Metabolic

Frequency not reported: Fluid retention, porphyria

Editorial References and Review

Medically reviewed by USARx EDITORIAL TEAM Last updated on 1/1/2020.

Source: Drugs.com Metoclopramide Odt (www.drugs.com/metoclopramide.html).